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Aims: To determine the antimicrobial activity of enacyloxin IIa and gladiolin
against Neisseria gonorrhoeae and Ureaplasma spp.
Methods and Results: The Burkholderia polyketide antibiotics enacyloxin IIa
and gladiolin were tested against 14 N. gonorrhoeae and 10 Ureaplasma spp.
isolates including multidrug-resistant N. gonorrhoeae isolates WHO V, WHO X
and WHO Z as well as macrolide, tetracycline and ciprofloxacin-resistant
ureaplasmas. Susceptibility testing of N. gonorrhoeae was carried out by agar
dilution, whereas broth micro-dilution and growth kinetic assays were used for
Ureaplasma spp. The MIC range for enacyloxin IIa and gladiolin against N.
gonorrhoeae was 0015–006 mg l1 and 1–2 mg l1 respectively. The presence
of resistance to front line antibiotics had no effect on MIC values. The MIC
range for enacyloxin IIa against Ureaplasma spp. was 4–32 mg l1 with a clear
dose-dependent effect when observed using a growth kinetic assay. Gladiolin
had no antimicrobial activity on Ureaplasma spp. at 32 mg l1 and limited
impact on growth kinetics.
Conclusions: Enacyloxin IIa and gladiolin antibiotics have antimicrobial
activity against a range of antibiotic susceptible and resistant N. gonorrhoeae
and Ureaplasma isolates.
Significance and Impact of the Study: This study highlights the potential for a
new class of antimicrobial against pathogens in which limited antibiotics are
available. Development of these compounds warrants further investigation in
the face of emerging extensively drug-resistant strains.
Introduction
Antimicrobial resistance (AMR) is of growing concern
among sexually transmitted pathogens. Neisseria gonor-
rhoeae diagnoses are increasing yearly which is ultimately
putting a pressure on increased prescribing and maybe
driving development of AMR (PHE 2019b). In many
countries resistance to ciprofloxacin persists, high-level
azithromycin resistance is present and resistance to third-
generation cephalosporins such as ceftriaxone has begun
to emerge (Unemo et al. 2019). In 2018, the first descrip-
tion of extensively drug-resistant (XDR) N. gonorrhoeae
was identified in the United Kingdom and subsequently
in Australia, with all cases linked to recent travel to South
East Asia (Eyre et al. 2018; Jennison et al. 2019). Further
reports of XDR cases with ceftriaxone resistance and
intermediate azithromycin resistance were reported in the
UK from two women with recent travel to Ibiza, Spain,
in which genomically identical strains belonging to the
characterized FC428 were isolated (Eyre et al. 2019).
Ureaplasma spp. are unique genus of bacteria which
have an essential requirement for urea in energy produc-
tion and also have one of the smallest genomes of any
free living organism (Glass et al. 2000). These bacteria are
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linked to non-gonococcal urethritis in men (Beeton et al.
2019) strongly associated with chorioamnionitis and sub-
sequent preterm birth, (Sweeney et al. 2017) development
of bronchopulmonary dysplasia, necrotizing enterocolitis
and intraventricular haemorrhaging among preterm neo-
nates (Viscardi 2014) and identified as a cause of infec-
tious hyperammonemia among immunocompromised
patients (Bharat et al. 2015). AMR is a significant chal-
lenge among these organisms due to substantial levels of
intrinsic resistance owing to the absence of a cell wall
and lack of metabolic pathways for de novo folic acid syn-
thesis. Current treatment relies on macrolide, fluoro-
quinolone and tetracycline antibiotics, although acquired
resistance is present to all antibiotics and prevalence
varies depending on geographical location (Beeton and
Spiller 2017). The lack of a cell wall affords Ureaplasma
spp. intrinsic resistance to all beta lactam and glycopep-
tide antibiotics, but also provides an excellent model
for ruling out cellular targets of novel antimicrobials
(Hillitt et al. 2017).
With the emergence of XDR N. gonorrhoeae and
presence of macrolide resistance among ureaplasmas,
which may complicate treatment of neonatal infections,
there is a growing need to develop antibiotics with
novel cellular targets to overcome current mechanisms
of resistance. Enacyloxin IIa (Mahenthiralingam et al.
2011) and gladiolin (Song et al. 2017) are novel polyke-
tide antibiotics isolated from Burkholderia bacteria.
These antimicrobial compounds are of interest due to
either their activity against novel bacterial targets not
targeted by currently approved antibiotics, or ability to
overcome current resistance as follows. Enacyloxin IIa
inhibits elongation factor-Tu (EF-Tu) which has not yet
been clinically exploited as an antibiotic target (Parmeg-
giani and Nissen 2006). The novel macrolide gladiolin
inhibits the bacterial RNA polymerase, but is able to
overcome resistance to other antibiotics such as rifam-
picin which has the same target (Song et al. 2017). The
antibacterial capacity of these compounds have been
examined against a number of bacteria including
Mycobacterium tuberculosis, Staphylococcus aureus, Ente-
rococcus faecium and Acinetobacter baumannii (Mahen-
thiralingam et al. 2011; Song et al. 2017), but to date
have yet to be examined against either N. gonorrhoeae
or any mollicute.
In this study, we examined the antimicrobial activity of
enacyloxin IIa and gladiolin against a panel of susceptible
and multidrug-resistant N. gonorrhoeae isolates from
South Wales and characterized collections. Additionally,
we sought to determine the activity of these compounds
against the cell wall-free Ureaplasma spp. as a representa-
tive of the Mollicutes class.
Materials and methods
Neisseria gonorrhoeae and Ureaplasma spp. strain
collection
A total of 14 N. gonorrhoeae were examined in this study.
Seven isolates (Gwent 1-7) were recent clinical isolates
from South Wales, UK. The remaining seven comprised
of characterized susceptible and multidrug-resistant iso-
lates NCTC 8375, NCTC 13798, NCTC 13799, NCTC
13477 (WHO F), NCTC 13818 (WHO V), NCTC 13820
(WHO X) and NCTC 13822 (WHO Z) (Unemo et al.
2016). Neisseria gonorrhoeae were propagated on Brain
Heart Infusion (BHI) agar (Sigma, Dorset, UK) supple-
mented with 5% lysed horse blood (TCS Biosciences,
Buckingham, UK). All cultures were incubated at 37°C in
the presence of CO2.
A total of 10 Ureaplasma spp. were tested. These
included Ureaplasma parvum serovar 1 (ATCC 27813),
U. parvum serovar 3 (ATCC 700970), U. parvum serovar
6 (ATCC 27818), U. parvum serovar 14 (ATCC 33697),
U. parvum HPA5, erythromycin-resistant U. parvum
UHWO10 (Beeton et al. 2009), ciprofloxacin-resistant U.
parvum U6 (Beeton et al. 2016), Ureaplasma urealyticum
serovar 2 (ATCC 27814), U. urealyticum serovar 4 (ATCC
27816) and tetracycline-resistant U. urealyticum serovar 9
(ATCC 33175). Ureaplasma were grown in ureaplasma
selective media (Mycoplasma Experience, Bletchingley,
UK) within microtitre plates and sealed with adhesive
film. Plates were incubated at 37°C under normal atmo-
spheric conditions. Antibiotics were purchased from
Sigma-Aldrich (Dorset, UK).
Preparation of enacyloxin IIa and gladiolin
Enacyloxin IIa and gladiolin were prepared from
Burkholderia gladioli strains BCC1701 and BCC0238
respectively. Both antibiotics were induced by growing
Burkholderia on solidified basal salts medium with 4 g l1
glycerol (BSM-G) for 72 h at 30°C and extracted using
dichloromethane (Mullins et al. 2019). Extracts were con-
centrated using a Buchi Rotavapor R-3 system, eluted in
60% (v/v) acetonitrile and purified by preparative HPLC
(Waters Autopurification HPLC system fitted with a XSe-
lect CSH C18, 5 µm OBD, 199 1009 mm column).
Fractions were collected at 360 and 230 nm for enacy-
loxin IIa and gladiolin respectively pooled and dried to a
powder by a combination of vacuum centrifugation and
freeze drying. Powdered aliquots of each antibiotic were
stored at 80°C prior to dissolving in dimethyl sulphox-
ide to create working stocks for antimicrobial susceptibil-
ity testing.
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Antimicrobial susceptibility testing of Ureaplasma spp
The susceptibility of Ureaplasma spp. to antimicrobials was
determined by broth microdilution following the Clinical
and Laboratory Standards Institute approved guidelines for
testing human mycoplasmas (CLSI 2011). In brief, dou-
bling dilutions of the test antimicrobial were prepared in
USM within microtitre plates. Ureaplasma were added to
each well giving a final concentration of 104–105 colour
changing units per ml. Plates were sealed and subsequently
incubated at 37°C under ambient air. MIC values were
determined as the lowest concentration of antimicrobial to
inhibit colour change at the point at which the positive
control well gave a colour change. Growth curve assays
were set up in an identical way with the modification of sta-
tic incubation within a Tecan Infinite M200 spectropho-
tometer. Plates were sealed and incubated at 37°C for 20 h
with readings taken at 550 nm were taken every 20 min.
Antimicrobial susceptibility testing of N. gonorrhoeae
Agar dilution was used to determine the susceptibility of
N. gonorrhoeae to the test antimicrobials. Briefly, dou-
bling dilutions of antimicrobials were prepared in agar
plates containing BHI supplemented with 5% defibrinized
horse blood giving a final concentration range from 32 to
0015 mg l1. Neisseria gonorrhoeae colonies were sus-
pended in saline to a 05 McFarland Standard. A multi-
point inoculator was used to inoculate plates with 1 µl of
bacterial suspension in duplicate. Plates were incubated
for 30 h at 37°C in the presence of CO2. For quality
assurance purposes, MIC values for the WHO strains
were confirmed using the method described.
Results
Activity of enacyloxin IIa and gladiolin against N.
gonorrhoeae
The activity of enacyloxin IIa and gladiolin against N.
gonorrhoeae was determined using an agar dilution assay.
The MIC range for enacyloxin IIa against N. gonorrhoeae
was lower than that of gladiolin (0015–006 mg l1 ver-
sus 1–2 mg l1 respectively) (Table 1). The presence of
defined high-level azithromycin resistance (WHO V) or
ceftriaxone resistance (WHO X) in a background of
ciprofloxacin and tetracycline resistance had no impact
on the MIC compared with fully susceptible strains.
Activity of enacyloxin IIa and gladiolin against
Ureaplasma spp
Using broth microdilution the MIC range of enacyloxin
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between 4 and 32 mg l1 whereas the MIC for gladi-
olin was greater than 32 mg l1 (Table 2). The effect
of enacyloxin IIa on the growth kinetics of the macro-
lide resistant U. parvum strain UHWO10 was deter-
mined by spectrophotometry (Fig. 1). There was a clear
dose-dependent inhibition of growth over time with
enacyloxin IIa, which was not seen with gladiolin or
erythromycin.
Discussion
Antibiotic resistance among sexually transmitted patho-
gens is of growing concern. In 2018, the first reports of
XDR N. gonorrhoeae with ceftriaxone and high-level azi-
thromycin resistance were noted in England and shortly
after in Australia (Jennison et al. 2019). Although num-
bers of XDR cases are limited, recent data from the






































32 32 4 8 16 4 8 16 4 32 10 4-32
Gladiolin >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 10 >32
Erythromycin 05 >32 05 1 1 05 1 1 05 2 10 05 to
>32
Ciprofloxacin 2 2 32 2 2 1 2 2 2 8 10 1–32
Tetracycline 025 0125 0125 0125 025 0125 0125 025 0125 >32 10 0125
to >32
U.u = U. urealyticum, U.p = U. parvum, SV = serovar.









































































Figure 1 Impact of antimicrobials on the growth dynamics of erythromycin-resistant Ureaplasma parvum isolate UHWO10. A colour change in
the culture media was recorded over time indicating growth of U. parvum while in the presence of varying concentration of (a) enacyloxin IIa, (b)
gladiolin and (c) erythromycin.
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Gonococcal Resistance to Antimicrobials Surveillance Pro-
gramme (GRASP) identified a drift in all antimicrobials
tested away from susceptible ranges (PHE 2019a). In light
of these data there is a need to invest and develop novel
antimicrobial compounds. Enacyloxin represents a novel
class of antibiotic for future development (Mahenthi-
ralingam et al. 2011). The MIC values for enacyloxin IIa
against N. gonorrhoeae were lower than for front line
agents azithromycin and ceftriaxone. The MIC values were
substantially lower than those previously reported for A.
baumannii (3 mg l1) and Pseudomonas aeruginosa
(100 mg l1; Mahenthiralingam et al. 2011). Of particular
interest was the activity of this compound against the
multidrug-resistant strains with documented resistance to
azithromycin, ceftriaxone, tetracycline and ciprofloxacin.
By inhibiting protein synthesis via interactions with EF-
TU, enacyloxin can bypass current mechanisms of resis-
tance. In addition, the recent finding that the chain release
mechanism required enacyloxin biosynthesis can be
manipulated to produce novel analogues, opens up multi-
ple possibilities for the clinical development of this antibi-
otic (Masschelein et al. 2019). Although the activity of
gladiolin was not as pronounced as enacyloxin IIa, it was
again comparable to that of azithromycin and ceftriaxone.
Ureaplasma spp. are recognized pathogens associated
with in utero infection, infection among immunocompro-
mised patients and mounting evidence as pathogens in sex-
ual health (Bharat et al. 2015; Sweeney et al. 2017; Beeton
et al. 2019). Intrinsic resistance to many antimicrobials and
emergence of acquired resistance makes treatment compli-
cated, especially in the context of neonatal infection in
which tetracyclines and fluoroquinolones are contraindica-
tions. Endpoint MIC readings showed that MIC values
ranged from 4 to 32 mg l1 for enacyloxin IIa and >32 for
gladiolin. These values were comparable to those previ-
ously seen for A. baumannii (Mahenthiralingam et al.
2011). Due to the lack of quantifiable turbidity when grow-
ing ureaplasma in broth culture, a colorimetric and kinetic
based method was used to observe any dose-dependent
impact of antimicrobials. For enacyloxin IIa there was a
clear dose dependent inhibition of growth which was
absent in the presence of gladiolin as well erythromycin to
which the UHWO10 is resistant to. Enaycyloxin is known
to bind serum proteins and therefore the presence of 20%
serum in the ureaplasma media may have chelated out
active drug explaining the higher MIC values. Reasons for
the lack of gladiolin activity is unknown, but may be linked
to the lack of antimicrobial activity against ureaplasmas
seen for other RNA polymerase inhibiting antibiotics such
as rifampin (Waites et al. 2005).
In conclusion, this study demonstrates the potential for
enacyloxin IIa and gladiolin as future therapeutics against
N. gonorrhoeae, with particular reference to multidrug-
resistant strains. These data suggest further investigation
and development of this compound as a potential for
treating XDR N. gonorrhoeae and mycoplasmas.
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